Baxter International Inc. Baxter International Inc.

Baxter International Inc.

BAX

Pozycja w akcjach #1641
Baxter International Inc., operating globally via its subsidiaries, is a... Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
Cena akcji
$25.29
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$13.07B
Zmiana (1 dzień)
-1.79%
Zmiana (1 rok)
9.51%
Kraj
US
Handel Baxter International Inc. (BAX)

Kategoria

Healthcare
Marża operacyjna dla Baxter International Inc. (BAX)
Marża operacyjna na dzień October 2026 TTM: -2.39%
Według najnowszych raportów finansowych i ceny akcji Baxter International Inc., bieżąca marża operacyjna (TTM) wynosi -2.39%. Na koniec 2023 wynosiła 6.82%.
Historia marży operacyjnej dla Baxter International Inc. od 2000 do 2026
Marża operacyjna na koniec każdego roku
Rok Marża operacyjna Zmień
2026 (TTM) -2.39% -1,938.46%
2024 0.13% -98.09%
2023 6.82% -124.11%
2022 -28.29% -354.64%
2021 11.11% -19.73%
2020 13.84% -11.28%
2019 15.60% 9.32%
2018 14.27% 17.26%
2017 12.17% 66.03%
2016 7.33% 62.89%
2015 4.50% -26.47%
2014 6.12% 16.13%
2013 5.27% -73.96%
2012 20.24% -4.53%
2011 21.20% 27.48%
2010 16.63% -27.38%
2009 22.90% 10.31%
2008 20.76% 7.84%
2007 19.25% 8.51%
2006 17.74% 6.61%
2005 16.64% 76.83%
2004 9.41% -33.40%
2003 14.13% -25.16%
2002 18.88% 13.53%
2001 16.63% 7.71%
2000 15.44% 0.00%
Marża operacyjna dla podobnych firm lub konkurentów
Firma Marża operacyjna Różnica w marży operacyjnej Kraj
31.28% -113.09%
US
12.36% -105.17%
FR
0.00% -
JP
9.83% -104.11%
US
0.00% -
CH
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.